玻璃体腔内注射康柏西普治疗继发性黄斑水肿疗效观察  

Observation the Intravitreal Injection of Conbercept Treatment of Secondary Macular Edema

作　　者：周美兰[1] 韩永钊 杨瑛[1] 栗慧娜[1] 

机构地区：[1]南京市江宁医院,江苏南京211100

出　　处：《中国医学创新》2016年第31期134-137,共4页Medical Innovation of China

摘　　要：目的：观察康柏西普玻璃体腔注射治疗继发性黄斑水肿有效性和安全性。方法：对继发于糖尿病视网膜病变及视网膜静脉阻塞的黄斑水肿患者35眼，予以玻璃体腔内注射康柏西普（0．5mg，0．05mL）进行治疗，随访1～3个月，观察治疗前及治疗后1d，1周，1、2、3个月患者最佳矫正视力，黄斑区中心厚度及眼压的变化。结果：患者最佳矫正视力在玻璃体腔注药后1周，1、2、3个月均较治疗前明显提高，比较差异均有统计学意义（P〈0．001）；黄斑区中心厚度在治疗后1周，1、2、3个月较治疗前明显降低，比较差异均有统计学意义（P〈0．001）；眼压在注药后1d，1周，1、2、3个月均无明显升高，比较差异均无统计学意义（P〉0．005）。结论：玻璃体腔内注射康博西普是目前治疗继发性黄斑水肿的有效而且安全的治疗手段，但部分患者黄斑水肿复发，需再次给药。Objective： To observe the efficacy and safety of Conbercept intravitreal injection treatment of secondary macular edema.Method： 35 patients with macular edema secondary to diabetic retinopathy and retinal vein occlusion were involved.These patients received intravitreal injection of Conbercept （ 0.5 mg, 0.05 mL ）, followed up for I to 3 months. Before treatment and after 1 day, 1 week, 1 month, 2 months, 3 months, the best corrected visual acuity, macular central thickness and intraocular pressure changes of all patients were observed. Result： The best corrected visual acuity of the patients were significantly improved with the vitreous cavity injection after 1 week, 1 month, 2 months and 3 months, the difference was statistically significant （P〈0.001） .The central thickness of the macular area was significantly lower after treatment 1 week, 1 month, 2 months and 3 months than before treatment, the difference was statistically significant （P〈0.001） .The intraocular pressure was not significant increased after treatment 1 week, 1 month, 2 months and 3 months, the difference was not statistically significant （P〉0.05） .Couclusion： Conbercept is an effective and safe therapy for the treatment of secondary maeular edema, but some patients have relapse of macular edema and need to be treated again.

关 键 词：康柏西普 玻璃体腔注射 黄斑水肿 

分 类 号：R774.5[医药卫生—眼科]